4-[3-[[(2S)-4-acetylmorpholin-2-yl]methyl]-7-methylimidazo[1,2-a]pyridin-2-yl]-N,3-dimethylbenzamide | 1621164-83-7

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: 4-[3-[[(2S)-4-acetylmorpholin-2-yl]methyl]-7-methylimidazo[1,2-a]pyridin-2-yl]-N,3-dimethylbenzamide
• CAS: 1621164-83-7
• 化学式: C₂₄H₂₈N₄O₃
• 分子量: 420.511
• InChiKey: PTCCIWHHNXWGPL-IBGZPJMESA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.9
• 重原子数：
  31
• 可旋转键数：
  4
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.38
• 拓扑面积：
  75.9
• 氢给体数：
  1
• 氢受体数：
  4

文献信息

• Imidazopyridine Compounds and Uses Thereof
  申请人：NEOMED INSTITUTE

  公开号：US20150361078A1

  公开（公告）日：2015-12-17

  This invention generally relates to substituted imidazopyridine compounds, particularly substituted 4-(imidazo[1,2-a]pyridin-2-yl)benzamide compounds and salts thereof. This invention also relates to pharmaceutical compositions and kits comprising such a compound, uses of such a compound (including, for example, treatment methods and medicament preparations), processes for making such a compound, and intermediates used in such processes.

  该发明通常涉及取代咪唑吡啶化合物，特别是取代的4-(咪唑[1,2-a]吡啶-2-基)苯甲酰胺化合物及其盐。该发明还涉及包含该化合物的药物组合物和试剂盒，以及该化合物的用途（包括治疗方法和药物制剂等），制备该化合物的过程以及用于该过程的中间体。
• IMIDAZOPYRIDINE COMPOUNDS AND USES THEREOF
  申请人：Neomed Institute

  公开号：EP2951177B1

  公开（公告）日：2018-04-04
• SELECTIVE P2X3 MODULATORS
  申请人：BELLUS HEALTH COUGH INC.

  公开号：US20200230148A1

  公开（公告）日：2020-07-23

  The current application relates to the use of a selective P2X3 antagonist for avoiding loss of taste response while treating a chronic cough in warm-blooded animals; wherein said selective P2X3 antagonist is selective for P2X3 homomeric receptor antagonism versus P2X2/3 heteromeric receptor antagonism.
• TREATMENT OF PRURITUS WITH P2X3 MODULATORS
  申请人：Bellus Health Cough Inc.

  公开号：US20210346391A1

  公开（公告）日：2021-11-11

  Methods of treating pruritus in a mammal with a P2X3 antagonist are disclosed. Said P2X3 antagonist is preferably a compound of Formula (I). Said pruritus may be associated with an inflammatory skin disorder, an infectious skin disease, an autoimmune skin disease or a pregnancy-related skin disease. The P2X3 antagonist may be administered by intravenous administration, subcutaneous administration, oral administration, inhalation, nasal administration, topical administration or ophthalmic administration and may be used in conjunction with a NK-1 antagonist. The P2X3 antagonist acts by inhibiting pathological ATP release associated with hyperexcitability of afferent pruriceptive neurons, thus dampening peripheral hypersensitivity to itch via broad mechanism independent on the pathological stimuli acting at itch receptors.
• TREATMENT WITH P2X3 MODULATORS
  申请人：BELLUS HEALTH COUGH INC.

  公开号：US20210386751A1

  公开（公告）日：2021-12-16

  Provided herein are methods for treating endometriosis, endometriosis-associated pain, and endometriosis-associated symptoms in a mammal in need thereof with a P2X3 modulator.